H.U. Group Holdings Inc. and its subsidiary Fujirebio Holdings, Inc., have announced that Fujirebio Diagnostics, Inc. has ...

Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers.

H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter“Fujirebio”) today announced that ...

Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a variety of diseases.

Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a ...

The Food and Drug Administration’s (FDA) approval of the first blood test to aid in the diagnosis of Alzheimer’s disease ...

Human Gene Sequencing Markets, Strategies, Trends and Forecasts Report 2025: Explore the New Opportunities Now That Sequencing has Gone Mainstream - ResearchAndMarkets.com ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease. The Food and Drug Administration cleared the test to replace PET ...

Fujirebio received clearance for Lumipulse back in May. The test was designated a "breakthrough device" by the FDA. It is the first blood-based in-vitro test for Alzheimer's to be cleared by the ...